-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 FE0nVg4y9W60k5doFmFd5gzezIEaG9b9lDKCjMDNCk+MBsbQ3VOo/NOXufD/oF48
 q5Iu+XWEYi1F8EJ4iO1LIQ==

<SEC-DOCUMENT>0001102624-04-000108.txt : 20040719
<SEC-HEADER>0001102624-04-000108.hdr.sgml : 20040719
<ACCEPTANCE-DATETIME>20040719144230
ACCESSION NUMBER:		0001102624-04-000108
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20040719
ITEM INFORMATION:		
ITEM INFORMATION:		Financial statements and exhibits
FILED AS OF DATE:		20040719

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUCELL CORP /DE/
		CENTRAL INDEX KEY:			0000811641
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				010382980
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12934
		FILM NUMBER:		04919915

	BUSINESS ADDRESS:	
		STREET 1:		56 EVERGREEN DR
		CITY:			PORTLAND
		STATE:			ME
		ZIP:			04103
		BUSINESS PHONE:		2078782770

	MAIL ADDRESS:	
		STREET 1:		56 EVERGREEN DRIVE
		CITY:			PORTLAND
		STATE:			ME
		ZIP:			04103
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>immucell8k.htm
<DESCRIPTION>IMMUCELL 8-K
<TEXT>
<table cellpadding="3" border="0" cellspacing="0" width="100%">
<tr><td>
</td></tr>
</table>
<center>
<table border=0 cellpadding=3 cellspacing=0>
<tr><td align="center"><br><br>
<B>UNITED STATES</B><br>
<B>SECURITIES AND EXCHANGE COMMISSION</B><br>
Washington, D.C. 20549<p>
<hr size=1>
<p><b>FORM 8-K<p>
CURRENT REPORT
<p>
Pursuant to Section 13 or 15(d) of the<br>Securities Exchange Act of 1934.
</td>
</tr>
</table>
<p>
<b>
<table border=0 cellpadding=0 cellspacing=0>
<tr><td colspan=5 align=center>
<b>Date of Report: July      19, 2004</b><br>
(Date of earliest event reported)<br><br>
</td></tr>
<tr><td colspan=5 align=center>
<b>ImmuCell Corporation</b><br>
(Exact name of registrant as specified in its charter)
</td></tr>
<tr>
<td align=center width="20%">
<b>DE</b><br>
(State or other jurisdiction of incorporation)
</td>
<td width="20%">
&nbsp;
</td>
<td align=center width="20%">
<b>0-15507</b><br>
(Commission File Number)
</td>
<td width="20%">
&nbsp;
</td>
<td align=center width="20%">
<b>01-0382980</b><br>
(IRS Employer Indentification Number)
</td>
</tr>
<tr>
<td width="20%">
&nbsp;
</td>
<td align=center width="20%" colspan=2>
<b>56 Evergreen Drive, Portland, ME</b><br>
(Address of principal executive offices)
</td>
<td align=center width="20%" colspan=2>
<b>04103</b><br>
(Zip Code)
</td>
<td width="20%">
&nbsp;
</td>
</tr>
<tr><td colspan=5 align=center>
<br>Registrant's telephone number, including area code: <b>(207) 878-2770</b>
</td></tr>
</table>
</center>
<hr size=1>
<table width=100%>
<tr><td width="100%">
<b>Item 7. Financial Statements and Exhibits</b></b><br>
<b>(a) Not Applicable</b><br>
<b>(b) Not Applicable</b><br>
<b>(c) Exhibits</b><br>
99.1 &nbsp; &nbsp; &nbsp; <a href="immucellcorporation.htm">Press Release of ImmuCell Corporation dated July      19, 2004</a></b>
<p>
<b>Item 12. Results of Operations and Financial Condition</b></b><br>
<br>
On July 19, 2004 ImmuCell Corporation (the "Company") issued a press release announcing the earnings results for the three and six month periods ended June 30, 2004. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K.
<br>
<br>The information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 of the Exchange Act, except as expressly set forth by specific reference in such filing.
<p>
<p>
<hr size=1>
<b><center>SIGNATURE</center></b>
<p>
&nbsp; &nbsp; &nbsp; Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be
              signed on its behalf by the undersigned hereunto duly authorized.<p>
</td></tr>
</table>
<table>
<tr>
<td width="50%" valign=top>
Dated: July      19, 2004<br>
</td>
<td>
<b>IMMUCELL CORPORATION</b>
<p>
By: <u>&nbsp;/s/ Michael F. Brigham &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; </u> <br>
&nbsp; &nbsp; &nbsp;Michael F. Brigham<br>
&nbsp; &nbsp; &nbsp;<i>President/CEO</i><br>
</td></tr>
</table>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1 CHARTER
<SEQUENCE>2
<FILENAME>immucellcorporation.htm
<DESCRIPTION>IMMUCELL PRESS RELEASE
<TEXT>

<p></p>
<b>ImmuCell Announces Sales Growth and Other Financial Results for Three and Six Months Ended June 30, 2004</b>
<p>PORTLAND, ME -- 07/19/2004 --  ImmuCell Corporation (NASDAQ: ICCC) today
announced the results of its operations for the three and six month periods
ended June 30, 2004.
</p>
<p>
For the three months ended June 30, 2004, product sales increased by 9%, or
$53,000, to $642,000, in comparison to the same period in 2003. For the six
months ended June 30, 2004, product sales increased by 16%, or $255,000, to
$1,860,000, in comparison to the same period in 2003.
</p>
<p>
"Our core business is experiencing steady sales growth, with expected
seasonal fluctuations," commented Michael F. Brigham, president and CEO,
"as we continue to fund the development of Mast Out&#174;."
</p>
<p>
The Company recognized a net loss of $58,000, or $0.02 per share, for the
three months ended June 30, 2004, compared to a net loss of $124,000, or
$0.05 per share, during the same period in 2003.  For the six months ended
June 30, 2004, the Company recognized income before income taxes of
$195,000. This compared with income before income taxes of $979,000 for the
same period in 2003, which included $1,100,000 in other income from the
sale of the Company's interest in a non-core joint venture.  Net income of
$114,000, or $0.04 per diluted share, was recognized for the six months
ended June 30, 2004, compared to net income of $577,000, or $0.21 per
diluted share, for the same period in 2003.
</p>
<p>
During the three month period ended June 30, 2004, research and development
expenses decreased by 16%, or $47,000, to $241,000, comprising 36% of total
revenues in 2004.  During the six month period ended June 30, 2004,
research and development expenses decreased by 23%, or $141,000, to
$463,000, comprising 24% of total revenues in 2004.  The primary focus of
the Company's research and development efforts continues to be Mast Out,
its Nisin-based treatment for mastitis in dairy cows. The research and
development expenses related to Mast Out are expected to increase in the
second half of the year.
</p>
<p>
The Company's cash and short-term investments increased by 1%, or $58,000,
to $4,303,000 at June 30, 2004, as compared to $4,245,000 at December 31,
2003.  Stockholders' equity increased by 2%, or $150,000, to $7,521,000 at
June 30, 2004, as compared to $7,370,000 at December 31, 2003.
</p>
<p>
ImmuCell Corporation is a biotechnology company that is developing products
intended to help reduce the overuse of antibiotics in animal and human
healthcare and is manufacturing and selling other products that improve
animal health and productivity in the dairy and beef industry.  ImmuCell
Corporation press releases and other information about the Company are
available at its corporate web site at http://www.immucell.com.
<pre>

                                       (Unaudited)          (Unaudited)
                                    Three Months Ended    Six Months Ended
(In thousands, except per                June 30,             June 30,
 share amounts)                       2004      2003       2004      2003
                                    -------   -------    -------   -------
Revenues:
Product sales                       $   642   $   590    $ 1,860   $ 1,605
Other revenues                           23        27         47       139
                                    -------   -------    -------   -------
Total revenues                          665       617      1,907     1,744

Cost and expenses:
Product costs                           300       284        759       709
Research and development expenses       241       289        463       604
Selling, general and
 administrative expenses                234       258        516       575
                                    -------   -------    -------   -------
Total costs and expenses                775       831      1,738     1,888
                                    -------   -------    -------   -------

Net operating (loss) income            (110)     (214)       169      (144)

Interest and other income                15        13         26     1,123
                                    -------   -------    -------   -------

(Loss) income before income taxes       (95)     (201)       195       979
Income tax (benefit) expense            (37)      (77)        81       402
                                    -------   -------    -------   -------
Net (loss) income                   $   (58)  $  (124)   $   114   $   577
                                    =======   =======    =======   =======

Net (loss) income per common share:
Basic                               $ (0.02)  $ (0.05)   $  0.04   $  0.21
Diluted                             $ (0.02)  $ (0.05)   $  0.04   $  0.21

Weighted average common
 shares outstanding:
Basic                                 2,758     2,736      2,751     2,736
Diluted                               2,961     2,736      2,947     2,794


                                   (Unaudited)
                                 At June 30, 2004      At December 31, 2003
                                 ----------------      --------------------
(In thousands)
Cash and short-term investments       $ 4,303                 $ 4,245
Total assets                            8,136                   8,187
Net working capital                     5,098                   4,965
Stockholders' equity                  $ 7,521                 $ 7,370
</pre>

</p>
<pre>
Contact:
Michael F. Brigham
President and Chief Executive Officer
(207) 878-2770 Ext. 3106


</pre>

</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
